Novo Nordisk Net Income 2006-2018 | NVO

Novo Nordisk annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Novo Nordisk net income for the quarter ending September 30, 2018 was $1.410B, a 8.67% decline year-over-year.
  • Novo Nordisk net income for the twelve months ending September 30, 2018 was $6.161B, a 7.62% increase year-over-year.
  • Novo Nordisk annual net income for 2017 was $5.792B, a 2.77% increase from 2016.
  • Novo Nordisk annual net income for 2016 was $5.636B, a 8.65% increase from 2015.
  • Novo Nordisk annual net income for 2015 was $5.187B, a 9.86% increase from 2014.
Novo Nordisk Annual Net Income
(Millions of US $)
2017 $5,792
2016 $5,636
2015 $5,187
2014 $4,722
2013 $4,485
2012 $3,703
2011 $3,195
2010 $2,568
2009 $2,017
2008 $1,851
2007 $1,568
2006 $1,084
2005 $979
Novo Nordisk Quarterly Net Income
(Millions of US $)
Q3 2018 $1,410
Q2 2018 $1,656
Q1 2018 $1,775
Q4 2017 $1,320
Q3 2017 $1,544
Q2 2017 $1,472
Q1 2017 $1,456
Q4 2016 $1,253
Q3 2016 $1,470
Q2 2016 $1,514
Q1 2016 $1,398
Q4 2015 $1,204
Q3 2015 $1,250
Q2 2015 $1,236
Q1 2015 $1,497
Q4 2014 $1,093
Q3 2014 $1,157
Q2 2014 $1,285
Q1 2014 $1,186
Q4 2013 $1,107
Q3 2013 $1,139
Q2 2013 $1,180
Q1 2013 $1,059
Q4 2012 $1,005
Q3 2012 $953
Q2 2012 $924
Q1 2012 $822
Q4 2011 $831
Q3 2011 $786
Q2 2011 $798
Q1 2011 $747
Q4 2010 $729
Q3 2010 $668
Q2 2010 $627
Q1 2010 $596
Q4 2009 $460
Q3 2009 $547
Q2 2009 $547
Q1 2009 $480
Q4 2008 $412
Q3 2008 $538
Q2 2008 $332
Q1 2008 $438
Q4 2007 $190
Q3 2007 $404
Q2 2007 $661
Q1 2007 $300
Q4 2006 $297
Q3 2006 $302
Q2 2006 $291
Q1 2006 $195
Q4 2005 $211
Q3 2005 $300
Q2 2005 $287
Q1 2005 $218
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $107.980B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14